VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Influenza virus HA protein vaccine (Influenza A virus (A/Yamagata/120/1986(H1N1)))
Vaccine Information
  • Vaccine Name: Influenza virus HA protein vaccine (Influenza A virus (A/Yamagata/120/1986(H1N1)))
  • Target Pathogen: Influenza virus
  • Target Disease: Influenza (flu)
  • Vaccine Ontology ID: VO_0004017
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Influenza A virus (A/Yamagata/120/1986(H1N1)) HA hemagglutinin
  • HA gene engineering:
    • Type: Recombinant protein preparation
    • Description: HA vaccines were prepared from influenza viruses A/PR/8/34 (H1NI), A. Yamagata/120/86 (HINI), A/ Fukuoka/C29/85 (H3N2) and B/Ibaraki/2/85 by the method of Davenport et al. in the Kitasato Institute, Tokyo, Japan (Tamura et al., 1989).

      Davenport, FM., Hennessy, A.V., Brandon, F.M., Webster, R.G.,Barrett, C.D. Jr. and Lease, G.O. Comparisons of serologic andfebrile responses in human to vaccination with influenza A viruses ortheir hemagglutinins. J. Lab. Clin. Med. 1964, 63, 5
    • Detailed Gene Information: Click Here.
  • Adjuvant: cholera toxin B subunit
  • Immunization Route: Intranasal
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were anaesthetized by an intraperitoneal injection of amobarbital sodium (0.25 ml of a solution of 1 p.g ml-1) and then immunized by an
    intranasal inoculation of 10lal phosphate-buffered saline (PBS) containing the required dose of HA vaccine and CTB (Tamura et al., 1989).
  • Challenge Protocol: Viral challenge four weeks after intranasal inoculation (Tamura et al., 1989).
  • Efficacy: The inoculation of HA vaccine prepared from influenza viruses A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) together with CTB provided partial protection against PR-8 infection in Balb/c mice (Tamura et al., 1989).
References
Tamura et al., 1989: Tamura SI, Samegai Y, Kurata H, Kikuta K, Nagamine T, Aizawa C, Kurata T. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine. 1989; 7(3); 257-262. [PubMed: 2781859].